News Releases

2022-09/22
1
2022-08/02
United BioPharma announces JCI publication of UB-221 mAb data demonstrating unique profiles of potent IgE neutralization, IgE synthesis reduction, and durable urticaria symptom relief
2
2022-05/26
United BioPharma Receives IND Approval from TFDA for A Phase 2 Study of UB-221 in Adults with Chronic Spontaneous Urticaria
3
2021-10/18
United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621
4
2021-08/18
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure
5
2021-07/15
United BioPharma Received IND Approval from China NMPA for a larger Phase 2 Trial with multi-dosing UB-621 to demonstrate optimal clinical efficacy in treatment of Recurrent Genital Herpes
6
2020-12/10
United BioPharma won the “2020 National Talent Development Award''
7
2020-11/11
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
8
2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
9
2022-09/22
1
2022-08/02
United BioPharma announces JCI publication of UB-221 mAb data demonstrating unique profiles of potent IgE neutralization, IgE synthesis reduction, and durable urticaria symptom relief
2
2022-05/26
United BioPharma Receives IND Approval from TFDA for A Phase 2 Study of UB-221 in Adults with Chronic Spontaneous Urticaria
3
2021-10/18
United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621
4
2021-08/18
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure
5
2021-07/15
United BioPharma Received IND Approval from China NMPA for a larger Phase 2 Trial with multi-dosing UB-621 to demonstrate optimal clinical efficacy in treatment of Recurrent Genital Herpes
6
2020-12/10
United BioPharma won the “2020 National Talent Development Award''
7
2020-11/11
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
8
2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
9